On June 16, 3SBio fell 5.79% in regular trading, trading at HK$16.11/share, with turnover of approximately HK$130 million. The decline came amid broad weakness across the biotechnology sector coupled with a notable rise in short-selling activity targeting the stock.

The biotech sector faced collective selling pressure, with peers AKESO falling 5.88%, Remegen declining 4.57%, and Co-Bridge Bio dropping 2.15%. Meanwhile, 3SBio's short-selling amount as a proportion of turnover surged to 18.74%, indicating heightened bearish positioning. Despite supportive actions — Chairman Lou Jing purchasing 516,000 shares at HK$15.25 per share on June 8, and Huatai-PineBridge Fund acquiring 636,500 shares at approximately HK$16.28 on June 10 — the stock remained under pressure from systemic sector rotation.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)